Clinical trials: Fibromyalgia, Pain
Fibromyalgia
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of…
- Trial name
- RESILIENT (NCT05273749)
- Testing
- TNX-102 SL Tablet, 5.6 mg
- Where
- 33 sites in United States
- Volunteers
- 457 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Fibromyalgia
Prospective Evaluation of Reduced Impedance Noninvasive Cortical Electrostimulation (RINCE) to Reduce Fibromyalgia Effects - Extension Study
The purpose of this open label study is to provide up to 24 active treatments of noninvasive cortical electrostimulation therapy only to those fibromyalgia patients who experienced inadequate pain reduction in a sham controlled…
- Trial name
- PERRFECT (NCT01958853)
- Testing
- RINCE
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Cerephex Corporation
Fibromyalgia, Painful Diabetic Peripheral Neuropathy
Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study
The investigators hypothesize that fibromyalgia (FM) and painful diabetic peripheral neuropathy (pDPN) patients with access restrictions on pregabalin will lead to higher healthcare resource use and cost compared to patients…
- Trial name
- NCT01280747
- Testing
- prior authorization, no prior authorization
- Where
- 17 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Fibromyalgia
Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia
The study was performed in participants suffering from fibromyalgia and investigated efficacy after treatment with several doses of GRT9906 versus placebo.
- Trial name
- NCT03783910
- Testing
- GRT9906
- Where
- 6 sites in United States
- Volunteers
- 90 people
- Sponsor
- Grünenthal GmbH
Fibromyalgia
Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients
The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia.
- Trial name
- NCT01271933
- Testing
- pregabalin
- Where
- 52 sites in United States, Canada and 2 more
- Volunteers
- 441 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibromyalgia, Chronic Pain
A Study of IMC-1 In Patients With Fibromyalgia
This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence.
- Conditions
- Fibromyalgia, Chronic Pain, Myofascial Pain
- Trial name
- NCT01850420
- Testing
- IMC-1
- Where
- 12 sites in United States
- Volunteers
- 143 people
- Sponsor
- Innovative Med Concepts, LLC
Myofascial Pain Syndromes
Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
The main purpose of this study is to determine the effectiveness and safety of one dose of botulinum toxin type A (Dysport) associated with rehabilitation treatment on pain control in patients with a type of back pain called…
- Trial name
- NCT00149240
- Testing
- Botulinum toxin type A
- Where
- 4 sites in Spain
- Volunteers
- 24 people
- Sponsor
- Ipsen